![Ulrik Nielsen](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Ulrik Nielsen
Fondatore presso MERRIMACK PHARMACEUTICALS, INC.
Profilo
Ulrik B.
Nielsen is the founder of Merrimack Pharmaceuticals, Inc. (founded in 1993) where he holds the title of Independent Director.
He was also the founder of Torque Therapeutics, Inc. (founded in 2015) where he held the title of Chairman & President from 2017 to 2018.
Dr. Nielsen's current job(s) include being the President, CEO, Treasurer & Director at Tidal Therapeutics, Inc. since 2018 and a Director at Alloy Therapeutics LLC since 2019.
Dr. Nielsen's former job(s) include being the Chief Executive Officer at Silver Creek Pharmaceuticals, Inc. from 2010 to 2014 and serving as the Executive Chairman-Management Board at Notch Therapeutics, Inc.Dr. Nielsen obtained his graduate and doctorate degrees from the University of Copenhagen.
Posizioni attive di Ulrik Nielsen
Società | Posizione | Inizio |
---|---|---|
MERRIMACK PHARMACEUTICALS, INC. | Fondatore | 01/01/1993 |
Tidal Therapeutics, Inc.
![]() Tidal Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Sanofi, Tidal Therapeutics, Inc. is a preclinical biotech company based in Quincy, MA. Tidal Therapeutics, Inc. focuses on developing nanoparticles that deliver to reprogram immune cells inside the body, with applications in oncology and immune diseases. Ulrik B. Nielsen has been the CEO of the company since 2018. Tidal Therapeutics was acquired by Sanofi on April 09, 2021 for $470 million. | Amministratore Delegato | 01/08/2018 |
Alloy Therapeutics LLC
![]() Alloy Therapeutics LLC Miscellaneous Commercial ServicesCommercial Services Alloy Therapeutics LLC is a biotechnology ecosystem company that democratizes access to tools, technologies, services, and company creation capabilities for discovering and developing therapeutic biologics. The company's lead offering is the ATX-GX™ platform, a human therapeutic antibody discovery platform consisting of a growing suite of proprietary transgenic mice strains. Through a community of partners across academia, biotech, and the largest biopharma, Alloy is a leader in bispecific antibody discovery and engineering services, utilizing its proprietary ATX-CLC common light chain platform integrating novel transgenic mice and phage display. Founded in 2017 and privately funded by visionary investors, Alloy is headquartered in Hanover, NH, with European labs in Switzerland. The company was founded by Errik B. Anderson, who has been the CEO since incorporation. | Direttore/Membro del Consiglio | 01/01/2019 |
Precedenti posizioni note di Ulrik Nielsen
Società | Posizione | Fine |
---|---|---|
Torque Therapeutics, Inc.
![]() Torque Therapeutics, Inc. BiotechnologyHealth Technology Torque Therapeutics, Inc. develops immunotherapies to address cancers focused on the specific modulation of immune cell subsets. The company was founded by Bart Henderson, Ulrik B. Nielsen, Darrell J. Irvine, and Thomas Lars Andresen and is headquartered in Cambridge, MA. | Amministratore Delegato | 14/11/2017 |
Silver Creek Pharmaceuticals, Inc.
![]() Silver Creek Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Silver Creek Pharmaceuticals, Inc. develops novel regenerative medicines. The firm focuses on treating cardiovascular disease. Its molecules are designed to promote resilience and regeneration of damaged tissues after acute or chronic injury. The company was founded in 2010 and is headquartered in San Francisco, CA. | Amministratore Delegato | 01/03/2014 |
Notch Therapeutics, Inc.
![]() Notch Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Notch Therapeutics, Inc. engages in the development of cell therapies for the treatment of diseases. It offers technology platform, which uses genetically tailored stem cells as a renewable source for creating allogeneic T cell therapies that expand treatment options and deliver cell immunotherapies to patients. The company was founded by Juan Carlos Zuniga-Pflucker and Peter Zandstra in 2018 and is headquartered in Toronto, Canada. | Amministratore Delegato | 20/07/2020 |
Formazione di Ulrik Nielsen
University of Copenhagen | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 6 |
---|---|
Merrimack Pharmaceuticals, Inc.
![]() Merrimack Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Merrimack Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. engages in discovering, developing, and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer. Its pipeline includes MM-131, MM-141, and MM-310. The company was founded by Anthony J. Sinskey, Gavin MacBeath, and Ulrik B. Nielsen in 1993 and is headquartered in Cambridge, MA. | Health Technology |
Silver Creek Pharmaceuticals, Inc.
![]() Silver Creek Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Silver Creek Pharmaceuticals, Inc. develops novel regenerative medicines. The firm focuses on treating cardiovascular disease. Its molecules are designed to promote resilience and regeneration of damaged tissues after acute or chronic injury. The company was founded in 2010 and is headquartered in San Francisco, CA. | Health Technology |
Torque Therapeutics, Inc.
![]() Torque Therapeutics, Inc. BiotechnologyHealth Technology Torque Therapeutics, Inc. develops immunotherapies to address cancers focused on the specific modulation of immune cell subsets. The company was founded by Bart Henderson, Ulrik B. Nielsen, Darrell J. Irvine, and Thomas Lars Andresen and is headquartered in Cambridge, MA. | Health Technology |
Notch Therapeutics, Inc.
![]() Notch Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Notch Therapeutics, Inc. engages in the development of cell therapies for the treatment of diseases. It offers technology platform, which uses genetically tailored stem cells as a renewable source for creating allogeneic T cell therapies that expand treatment options and deliver cell immunotherapies to patients. The company was founded by Juan Carlos Zuniga-Pflucker and Peter Zandstra in 2018 and is headquartered in Toronto, Canada. | Health Technology |
Tidal Therapeutics, Inc.
![]() Tidal Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Sanofi, Tidal Therapeutics, Inc. is a preclinical biotech company based in Quincy, MA. Tidal Therapeutics, Inc. focuses on developing nanoparticles that deliver to reprogram immune cells inside the body, with applications in oncology and immune diseases. Ulrik B. Nielsen has been the CEO of the company since 2018. Tidal Therapeutics was acquired by Sanofi on April 09, 2021 for $470 million. | Commercial Services |
Alloy Therapeutics LLC
![]() Alloy Therapeutics LLC Miscellaneous Commercial ServicesCommercial Services Alloy Therapeutics LLC is a biotechnology ecosystem company that democratizes access to tools, technologies, services, and company creation capabilities for discovering and developing therapeutic biologics. The company's lead offering is the ATX-GX™ platform, a human therapeutic antibody discovery platform consisting of a growing suite of proprietary transgenic mice strains. Through a community of partners across academia, biotech, and the largest biopharma, Alloy is a leader in bispecific antibody discovery and engineering services, utilizing its proprietary ATX-CLC common light chain platform integrating novel transgenic mice and phage display. Founded in 2017 and privately funded by visionary investors, Alloy is headquartered in Hanover, NH, with European labs in Switzerland. The company was founded by Errik B. Anderson, who has been the CEO since incorporation. | Commercial Services |
- Borsa valori
- Insiders
- Ulrik Nielsen